Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 2, 2008, Pages 423-424

  Simon, Dagmar ^a   Wittwer, Jennifer ^a   Kostylina, Ganna ^a   Buettiker, Urs ^a   Simon, Hans Uwe ^a   Yawalkar, Nikhil ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; FAS ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5;

ACANTHOSIS; ADULT; ATOPIC DERMATITIS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EOSINOPHIL; FEMALE; FOLLOW UP; HUMAN; HYPERKERATOSIS; LETTER; LEUKOCYTE; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; NEUTROPHIL; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADULT; CYTOKINES; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 48349090587     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.06.010     Document Type: Letter

References (7)

1. Johnson J.G., and Jenkins M.K. Accessory cell-derived signals required for T cell activation. Immunol Res 12 (1993) 48-64
2. Miller G.T., Hochman P.S., Meier W., Tozard R., Bixler S., Rosa M., et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178 (1993) 211-222
3. Cooper J.C., Morgan G., Harding S., Subramanyam M., Majeau G.R., Moulder K., et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol 33 (2003) 666-675
4. Simon D., Hösli S., Kostylina G., Yawalkar N., and Simon H.U. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121 (2008) 122-128
5. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
6. Perlmutter A., Cather J., Franks B., Jaracz E., and Menter A. Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 58 (2008) 116-124
7. Akdis C.A., Akdis M., Simon H.U., and Blaser K. Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int Arch Allergy Immunol 118 (1999) 140-144